Clinical trial

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

NCT05501548

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2023-06-30

PhasePHASE2

Study timeline

Study start (actual)2023-06-30Date precision: day

Registry last updated2025-01-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Castration-resistant Prostate Cancerunresolved

Interventions

OlaparibDRUG · verified · RxNorm: olaparib

Vitamin CDIETARY_SUPPLEMENT

Sponsors & collaborators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinslead sponsor

AstraZenecacollaborator

McGuff Pharmaceuticals, Inc.collaborator

The Marcus Foundationcollaborator

Mapped research locations

BaltimoreMaryland, United States1 Washington D.C.District of Columbia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05501548 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.